New hope for UC patients: early biologic treatment may beat standard therapy
NCT ID NCT07235904
First seen Nov 19, 2025 · Last updated Jun 13, 2026 · Updated 24 times
Summary
This study compares two treatment approaches for people newly diagnosed with moderate-to-severe ulcerative colitis (UC). One group gets early treatment with mirikizumab, a biologic drug, while the other starts with standard azathioprine pills and can switch to mirikizumab later if needed. The goal is to see if starting with mirikizumab leads to better disease control and fewer side effects over 52 weeks. About 300 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Schleswig-Holstein
RECRUITINGKiel, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.